Clinical Trial

A Study of Mirdametinib in People With Central Nervous System Tumors

Name: A Study of Mirdametinib in People With Central Nervous System Tumors — clinical trial record (NCT07539441)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2026-04-13; most recent amendment 2026-05-12.

Trial Details

NCT Number	NCT07539441
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: SpringWorks Therapeutics, Inc.
Conditions	Central Nervous System Tumors, Glioma
Enrollment	26 participants
Start Date	2026-04-10
Primary Completion	2029-10-10 (estimated)
Study Completion	2029-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-05-13